Skip to Content
Merck
CN
  • Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia rats.

Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia rats.

Acta pharmacologica Sinica (2014-09-16)
Qiu-yu Xu, Yin-hui Liu, Qi Zhang, Bo Ma, Zhen-dong Yang, Lei Liu, Di Yao, Guang-bo Cui, Jing-jing Sun, Zi-mei Wu
ABSTRACT

To investigate the metabolite changes caused by simvastatin or fenofibrate intervention in diet-induced hyperlipidemia rats using a GC-MS-based metabolomic profiling approach. SD rats were fed with high-lipid diet for 4 weeks to induce hyperlipidemia, then the rats were fed with normal diet, and orally administered with simvastatin (10 mg·kg(-1)·d(-1)) or fenofibrate (150 mg·kg(-1)·d(-1)) for 2 weeks. Blood samples were collected once a week, and potential biomarkers were examined using commercial assay kits and a metabolomic approach. The metabolomics data were analyzed using a multivariate statistical technique and a principal component analysis (PCA). Oral administration of simvastatin or fenofibrate significantly decreased the plasma levels of total cholesterol (TC) and low-density lipoprotein (LDL) cholesterol and increased the plasma level of high-density lipoprotein (HDL) cholesterol in the hyperlipidemia rats. Plasma samples were scattered in the PCA scores plots in response to the diet and to the drugs administered. The main metabolites changed in the hyperlipidemia rats were cholesterol, creatinine, linoleic acid, β-hydroxybutyric acid, tyrosine, isoleucine and ornithine. The plasma level of creatinine was significantly lower in the simvastatin-treated rats than in the fenofibrate-treated rats. The plasma tyrosine concentration was declined following intake of high-lipid diet, which was reversed by fenobrate, but not by simvastatin. A series of potential biomarkers including tyrosine, creatinine, linoleic acid, β-hydroxybutyric acid and ornithine have been identified by metabolomic profiling, which may be used to identify the metabolic changes during hyperlipidemia progression.

MATERIALS
Product Number
Brand
Product Description

Supelco
Heptane, analytical standard
Sigma-Aldrich
Heptane, ReagentPlus®, 99%
Supelco
Chlorotrimethylsilane, derivatization grade (GC derivatization), LiChropur, ≥99.0% (GC)
Sigma-Aldrich
Chlorotrimethylsilane, Wacker Chemie AG, ≥99.0% (GC)
Sigma-Aldrich
Chlorotrimethylsilane, purified by redistillation, ≥99%
Sigma-Aldrich
Chlorotrimethylsilane, ≥98.0% (GC)
Sigma-Aldrich
Chlorotrimethylsilane, puriss., ≥99.0% (GC)
Supelco
N-Methyl-bis(trifluoroacetamide), derivatization grade (GC derivatization), LiChropur, ≥99.0% (GC)
Sigma-Aldrich
Heptane, suitable for HPLC, ≥99%
Sigma-Aldrich
Heptane, suitable for HPLC, ≥96%
Sigma-Aldrich
Heptane, anhydrous, 99%
Sigma-Aldrich
Heptane, HPLC Plus, for HPLC, GC, and residue analysis, 99%
Sigma-Aldrich
Heptane, puriss. p.a., reag. Ph. Eur., ≥99% n-heptane basis (GC)
Supelco
Heptane, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Heptane, biotech. grade, ≥99%
Supelco
N-Methyl-bis(trifluoroacetamide), derivatization grade (GC derivatization), LiChropur, ≥97.0% (GC)
Supelco
Acetic anhydride, derivatization grade (GC derivatization), LiChropur, ≥99.0%
Sigma-Aldrich
Chlorotrimethylsilane solution, 1.0 M in THF
Supelco
N-Methyl-N-(trimethylsilyl)trifluoroacetamide, BioReagent, for silylations, LiChropur
Supelco
N-Methyl-N-(trimethylsilyl)trifluoroacetamide, derivatization grade (GC derivatization), LiChropur, ≥98.5%
Supelco
N-Methyl-N-(trimethylsilyl)trifluoroacetamide, synthesis grade
Sigma-Aldrich
Acetic anhydride, ACS reagent, ≥98.0%
Sigma-Aldrich
Acetic anhydride, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99% (GC)
Sigma-Aldrich
Acetic anhydride, ReagentPlus®, ≥99%
Supelco
N-Methyl-N-(trimethylsilyl)trifluoroacetamide with 1% trimethylchlorosilane, derivatization grade (GC derivatization), LiChropur